Rna interactome capturing protocol and antiviral composition discovered using same
AssigneesSeoul National University R&Db Foundation, Institute for Basic Science
InventorsV. Narry KIM, Sungyul LEE, Young-suk LEE
Life of this patent
Estimating the term…
Abstract
The present invention relates to an RNA interactome capturing protocol and an antiviral composition discovered using same. When used, the antiviral composition and pharmaceutical composition of the present invention can effectively inhibit viral infection and suppress viral proliferation in vivo after viral infection.
Claims13
-9. (canceled)
A screening method for a coronavirus inhibitor comprising the following steps:
- (a) contacting coronavirus-infected cells with a candidate substance for a coronavirus inhibitor;
- and
- (b) analyzing whether the expression level of one or more proteins selected from the group consisting of EIF3A, EIF3D, CSDE1, HNRNPM, YBX3, FMR1, RTCB, and NUFIP2 is reduced compared to a control group of cells not treated with the candidate substance, to determine the candidate substance as a coronavirus inhibitor if the expression level of the proteins is reduced.
A method for establishing an RNA interactome comprising the following steps:
- (a) inducing the RNA-protein cross-linking by irradiating a sample containing target RNA and protein with UV light;
- (b) performing Denaturation by DNase treatment;
- (c) capturing denatured RNP complexes in a sequence-specific manner using a biotinylated antisense oligonucleotide probe pool;
- wherein the biotinylated antisense oligonucleotides included in the probe pool are designed based on the target RNA sequence in a consecutive manner, and have the same length ranging from 45 to 135 nt, and their starting positions are spaced at regular intervals to induce partial overlap between the oligonucleotides;
- (d) performing Digestion by on-bead trypsin treatment;
- and
- (e) obtaining interactome information through analysis of the digestion products.
A method for treating virus infection, comprising a step of administering an antiviral composition to a subject in need of administration, wherein the antiviral composition comprises one or more proteins selected from the group consisting of LARP1, FUBP3, FUBP1, FAM120A, FAM120C, EIF4H, RPS3, RPS9, SND1, CELF1, RALY, CNBP, TRIM25, ZC3HAV1, PARP12, PPP1CA, HDLBP, CNBP, TIAL, UPF1, and SHFL as an active ingredient.
Dependencies are inferred from the claim text.